Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

LGND

Ligand Pharmaceuticals, Inc

Dec 13 • 04:00PM ET

116.91

Dollar change +3.40
Percentage change 3.00	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BIIB GILD INCY AMGN BMY PFE MRNA RDY

| Held by: IJR IWM VTI VB VBR VXF IJS IWN SPSM IBB

Scroll to Statements

Index	RUT	P/E	46.51	EPS (ttm)	2.51	Insider Own	2.23%	Shs Outstand	18.76M	Perf Week	-6.34%
Market Cap	2.28B	Forward P/E	19.27	EPS next Y	6.07	Insider Trans	-11.76%	Shs Float	18.47M	Perf Month	-4.23%
Income	45.24M	PEG	3.10	EPS next Q	1.18	Inst Own	97.03%	Short Float	4.25%	Perf Quarter	11.34%
Sales	152.42M	P/S	14.93	EPS this Y	-7.37%	Inst Trans	4.84%	Short Ratio	6.96	Perf Half Y	46.03%
Book/sh	44.84	P/B	2.61	EPS next Y	7.57%	ROA	5.25%	Short Interest	0.79M	Perf Year	73.77%
Cash/sh	11.29	P/C	10.36	EPS next 5Y	15.00%	ROE	6.00%	52W Range	62.83 - 129.90	Perf YTD	63.69%
Dividend Est.	-	P/FCF	30.80	EPS past 5Y	-13.18%	ROI	5.34%	52W High	-10.00%	Beta	1.06
Dividend TTM	-	Quick Ratio	11.70	Sales past 5Y	-3.89%	Gross Margin	71.86%	52W Low	86.07%	ATR (14)	5.04
Dividend Ex-Date	Jul 02, 2010	Current Ratio	12.49	EPS Y/Y TTM	172.65%	Oper. Margin	11.79%	RSI (14)	49.21	Volatility	5.59% 4.34%
Employees	58	Debt/Eq	0.01	Sales Y/Y TTM	-0.76%	Profit Margin	29.68%	Recom	1.14	Target Price	142.38
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	34.12%	Payout	0.00%	Rel Volume	0.95	Prev Close	113.51
Sales Surprise	27.63%	EPS Surprise	36.59%	Sales Q/Q	57.64%	Earnings	Nov 07 BMO	Avg Volume	112.84K	Price	116.91
SMA20	-1.31%	SMA50	2.88%	SMA200	23.76%	Trades		Volume	107,185	Change	3.00%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-03-24	Initiated	Oppenheimer	Outperform	$135
Jul-30-24	Initiated	RBC Capital Mkts	Outperform	$130
Apr-14-21	Resumed	Stephens	Overweight	$200
Feb-04-21	Reiterated	H.C. Wainwright	Buy	$229 → $310
Oct-06-20	Initiated	Barclays	Overweight	$156
Mar-24-20	Downgrade	Argus	Buy → Hold
Mar-10-20	Initiated	Guggenheim	Neutral
Feb-06-20	Initiated	The Benchmark Company	Buy	$135
Sep-19-19	Upgrade	Barclays	Equal Weight → Overweight	$110 → $132
Jun-11-19	Initiated	Barclays	Equal Weight	$131
May-03-19	Reiterated	H.C. Wainwright	Buy	$254 → $214
Mar-06-19	Reiterated	H.C. Wainwright	Buy	$281 → $254
Oct-29-18	Upgrade	ROTH Capital	Neutral → Buy
Oct-02-18	Reiterated	H.C. Wainwright	Buy	$270 → $280
Sep-11-18	Reiterated	Argus	Buy	$260 → $300
Aug-17-18	Initiated	Goldman	Neutral	$256
Aug-08-18	Downgrade	ROTH Capital	Buy → Neutral
Jun-21-18	Initiated	Argus	Buy	$260
Dec-27-17	Reiterated	H.C. Wainwright	Buy	$163 → $169
Sep-05-17	Resumed	H.C. Wainwright	Buy	$150

Show Previous Ratings

Dec-12-24 07:45AM	Ligand price target raised to $151 from $135 at Oppenheimer (TipRanks) -5.69%
Dec-10-24 09:00AM	Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance (Business Wire)
Nov-14-24 08:00AM	Ligand to Present at Stifel 2024 Healthcare Conference (Business Wire) -5.43%
Nov-07-24 07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire) +11.12%
Nov-01-24 08:01AM	Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston (Business Wire)
04:01PM	Loading…
Oct-23-24 04:01PM	Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
Oct-17-24 07:30AM	Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer (GlobeNewswire)
Sep-06-24 09:20AM	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (Business Wire)
Aug-20-24 09:00AM	Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference (Business Wire)
Aug-06-24 04:01PM	Ligand Reports Second Quarter 2024 Financial Results (Business Wire) -5.78%
Jul-24-24 06:30AM	Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement (ACCESSWIRE)
Jul-23-24 04:01PM	Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 (Business Wire)
Jul-08-24 07:00AM	Ligand to Acquire APEIRON Biologics AG for $100 Million (Business Wire)
Jul-01-24 08:00AM	Lifecore Biomedical Announces Cooperation Agreement with 22NW (GlobeNewswire)
Jun-27-24 08:00AM	Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years (Business Wire) +5.80%
08:00AM	Loading…
Jun-18-24 08:00AM	Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine) for Adults (Business Wire)
Jun-14-24 12:00PM	What Makes Ligand (LGND) a New Strong Buy Stock (Zacks)
Jun-06-24 11:31AM	Why Is Ligand (LGND) Up 4% Since Last Earnings Report? (Zacks)
Jun-04-24 09:55AM	Does Ligand (LGND) Have the Potential to Rally 32.33% as Wall Street Analysts Expect? (Zacks) -8.05%
08:50AM	Recent Price Trend in Ligand (LGND) is Your Friend, Here's Why (Zacks)
May-23-24 04:59PM	Ligand to Participate in Upcoming Investor Conferences (Business Wire)
May-20-24 06:00AM	3 Must-Buy Biotech Stocks Before the Summer Rally Kicks Off (InvestorPlace)
May-13-24 12:00PM	Ligand (LGND) Moves to Strong Buy: Rationale Behind the Upgrade (Zacks)
May-10-24 08:50AM	Ligand (LGND) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-09-24 09:40AM	Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year? (Zacks) +7.17%
May-08-24 01:22PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript (Insider Monkey) +9.75%
12:19PM	Ligand (LGND) Beats Q1 Earnings, Misses Sales Estimates (Zacks)
May-07-24 09:01PM	LGND Stock Earnings: Ligand Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM	Ligand Pharmaceuticals (LGND) Tops Q1 Earnings Estimates (Zacks)
04:00PM	Ligand Reports First Quarter 2024 Financial Results (Business Wire)
11:29AM	Loading…
11:29AM	Travere Therapeutics, Inc. (NASDAQ:TVTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:30AM	Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement (Business Wire)
Apr-23-24 08:31AM	Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
Apr-17-24 09:55AM	Wall Street Analysts Predict a 45.56% Upside in Ligand (LGND): Here's What You Should Know (Zacks)
Apr-08-24 08:15AM	Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference (Business Wire)
Apr-05-24 06:00PM	Ligand Pharmaceuticals (LGND) Stock Dips While Market Gains: Key Facts (Zacks)
Apr-04-24 09:30AM	Wall Street Analysts Think Ligand (LGND) Is a Good Investment: Is It? (Zacks)
09:00AM	Investors Heavily Search Ligand Pharmaceuticals Incorporated (LGND): Here is What You Need to Know (Zacks)
Apr-03-24 09:00AM	Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI (Business Wire)
Apr-01-24 06:15PM	Ligand Pharmaceuticals (LGND) Ascends While Market Falls: Some Facts to Note (Zacks)
Mar-28-24 11:30AM	Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-26-24 06:15PM	Ligand Pharmaceuticals (LGND) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Mar-21-24 09:00AM	Here is What to Know Beyond Why Ligand Pharmaceuticals Incorporated (LGND) is a Trending Stock (Zacks)
Mar-20-24 06:00PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Mar-19-24 09:30AM	Ligand (LGND) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
Mar-14-24 06:00PM	Ligand Pharmaceuticals (LGND) Declines More Than Market: Some Information for Investors (Zacks)
Mar-07-24 09:00AM	Is Trending Stock Ligand Pharmaceuticals Incorporated (LGND) a Buy Now? (Zacks)
Mar-05-24 04:01PM	Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference (Business Wire)
Mar-04-24 08:00AM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-29-24 09:30AM	Wall Street Analysts See Ligand (LGND) as a Buy: Should You Invest? (Zacks) -5.93%
Feb-28-24 07:34AM	Ligand (LGND) Q4 Earnings Surpass Estimates, Stock Surges (Zacks) -5.44%
Feb-27-24 07:00AM	Ligand Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire) +19.86%
Feb-22-24 04:01PM	Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa (Business Wire)
Feb-16-24 08:00AM	Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires (Business Wire)
Feb-13-24 04:01PM	Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (Business Wire) -6.13%
Feb-01-24 05:00PM	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-10-24 07:30PM	Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy Lasofoxifene (GlobeNewswire)
Jan-05-24 04:30PM	U.S. Food and Drug Administration Approves ZELSUVMI as a First-in-Class Medication for the Treatment of Molluscum Contagiosum (Business Wire)
Dec-12-23 12:01PM	Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance (Business Wire)
09:00AM	Sermonix Pharmaceuticals Shares Results of Third Survey on ESR1 and Metastatic Breast Cancer Patient Quality of Life (GlobeNewswire)
09:00AM	Sermonix Pharmaceuticals Shares Pharmacokinetic and Baseline Genomic Clinical Data Tied to ELAINE Lasofoxifene Trials of Patients With ESR1 Mutations (GlobeNewswire)
Dec-11-23 09:00AM	Sermonix Pharmaceuticals Announces Publication of ELAINE-1 and ELAINE-2 Trial Results in Annals of Oncology (GlobeNewswire)
Dec-06-23 04:02PM	Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City (Business Wire)
Dec-01-23 08:20AM	Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical Indications (GlobeNewswire)
Nov-28-23 09:01AM	Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-09-23 04:47PM	Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 04:01PM	Ligand Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-06-23 09:00AM	Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial (GlobeNewswire)
Nov-01-23 08:00AM	Ligand Acquires Royalty on Sanofis TZIELD for $20 Million (Business Wire)
Oct-25-23 04:01PM	Ligand To Report Third Quarter 2023 Financial Results On November 8 (Business Wire)
Oct-18-23 08:00AM	Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid's Cash Runway into 2026 (GlobeNewswire)
Oct-09-23 06:15PM	Ligand Pharmaceuticals (LGND) Exceeds Market Returns: Some Facts to Consider (Zacks)
Oct-03-23 06:00PM	Ligand Pharmaceuticals (LGND) Stock Moves -0.71%: What You Should Know (Zacks)
Oct-02-23 09:00AM	Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast Cancer (GlobeNewswire)
09:00AM	Sermonix Pharmaceuticals Announces Results of ELAINE-1 Exploratory Analysis Evaluating Effect of Patient Characteristics on Baseline Genitourinary Symptoms (GlobeNewswire)
Sep-27-23 09:00AM	Ligand Acquires Assets of Novan, Inc. for $12.2 Million (Business Wire)
Sep-26-23 05:05PM	Ligand Appoints Martine Zimmermann to its Board of Directors (Business Wire)
Sep-22-23 09:00AM	Ligands Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (Business Wire)
Sep-21-23 09:20AM	Ligands Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control (Business Wire)
Sep-18-23 05:17PM	Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio (Business Wire)
Sep-01-23 10:02PM	Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Business Wire)
Aug-08-23 04:01PM	Ligand Reports Second Quarter 2023 Financial Results (Business Wire) +5.35%
Jul-27-23 01:30PM	Ligands Collaborator Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials (Business Wire)
Jul-25-23 04:30PM	Ligand To Report Second Quarter 2023 Financial Results On August 8 (Business Wire)
Jul-17-23 08:59AM	Ligand Offers $15 Million to Acquire Assets of Novan, Inc. (Business Wire)
08:45AM	Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 Protection (GlobeNewswire)
Jun-29-23 09:00AM	Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual Meeting (GlobeNewswire)
Jun-21-23 08:00PM	LGND: Lowering target price to $81.00 (Argus Research)
Jun-09-23 09:40AM	Is Ligand Pharmaceuticals (LGND) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-06-23 11:40AM	LGND or ILMN: Which Is the Better Value Stock Right Now? (Zacks)
11:10AM	UnitedHealth (UNH) Intends to Buy Amedisys to Boost Home-Health (Zacks)
Jun-05-23 11:49AM	Oncorus (ONCR) Dips 37% on Layoff Plan & Bankruptcy Threat (Zacks) -5.72%
09:01AM	Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast Cancer (GlobeNewswire)
Jun-02-23 12:39PM	FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer (Zacks) +5.77%
12:35PM	Ionis (IONS) Posts Two-Year Upbeat Data From HAE Drug Study (Zacks)
Jun-01-23 11:29AM	Biohaven (BHVN) Stock up 8% on Encouraging Pipeline Updates (Zacks)
May-30-23 07:01PM	3 Stocks That Smart Investors Should Be Flocking to Now (InvestorPlace)
May-25-23 05:00PM	Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023 (GlobeNewswire)
May-24-23 09:55AM	Wall Street Analysts Think Ligand (LGND) Could Surge 44.42%: Read This Before Placing a Bet (Zacks)
09:40AM	Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year? (Zacks)

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in Jupiter, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LAMATTINA JOHN L	Director	Nov 27 '24	Option Exercise	52.30	2,406	125,834	31,921	Dec 02 08:05 PM
LAMATTINA JOHN L	Director	Nov 27 '24	Sale	123.65	2,406	297,502	29,515	Dec 02 08:05 PM
LAMATTINA JOHN L	Director	Nov 26 '24	Proposed Sale	119.19	2,406	286,771		Nov 27 04:44 PM
Korenberg Matthew E	Officer	Nov 11 '24	Proposed Sale	120.33	32,183	3,872,684		Nov 12 10:25 AM
Reardon Andrew	CLO & Secretary	Sep 23 '24	Option Exercise	52.27	2,000	104,540	24,534	Sep 25 08:54 PM
Reardon Andrew	CLO & Secretary	Sep 23 '24	Sale	99.60	2,000	199,201	22,534	Sep 25 08:54 PM
Espinoza Octavio	Chief Financial Officer	Sep 20 '24	Sale	103.94	1,275	132,518	24,610	Sep 24 07:41 PM
Korenberg Matthew E	President & COO	Sep 23 '24	Option Exercise	52.72	9,772	515,227	60,549	Sep 24 07:41 PM
Korenberg Matthew E	President & COO	Sep 20 '24	Option Exercise	49.99	4,982	249,050	57,052	Sep 24 07:41 PM
Korenberg Matthew E	President & COO	Sep 23 '24	Sale	101.22	9,772	989,121	50,777	Sep 24 07:41 PM
Korenberg Matthew E	President & COO	Sep 20 '24	Sale	104.10	6,275	653,238	50,777	Sep 24 07:41 PM
Reardon Andrew	Officer	Sep 23 '24	Proposed Sale	99.60	2,000	199,201		Sep 23 05:30 PM
Korenberg Matthew E	Officer	Sep 23 '24	Proposed Sale	101.50	14,437	1,465,403		Sep 23 05:27 PM
Korenberg Matthew E	Officer	Sep 20 '24	Proposed Sale	104.10	6,275	653,238		Sep 20 06:12 PM
Espinoza Octavio	Officer	Sep 20 '24	Proposed Sale	103.94	1,275	132,518		Sep 20 05:39 PM
Espinoza Octavio	Chief Financial Officer	Sep 17 '24	Option Exercise	79.63	1,486	118,328	25,885	Sep 19 05:50 PM
Korenberg Matthew E	President & COO	Sep 16 '24	Option Exercise	58.49	5,774	337,696	54,008	Sep 18 07:55 PM
Espinoza Octavio	Chief Financial Officer	Aug 28 '24	Option Exercise	66.52	753	50,086	24,399	Aug 30 09:00 PM
Reardon Andrew	CLO & Secretary	Aug 28 '24	Option Exercise	52.27	1,500	78,405	24,034	Aug 30 08:56 PM
Reardon Andrew	CLO & Secretary	Aug 28 '24	Sale	106.39	1,500	159,591	22,534	Aug 30 08:56 PM
Reardon Andrew	Officer	Aug 28 '24	Proposed Sale	106.39	1,500	159,590		Aug 28 04:39 PM
Korenberg Matthew E	President & COO	Aug 26 '24	Sale	105.61	11,389	1,202,831	49,510	Aug 26 08:15 PM
Korenberg Matthew E	President & COO	Aug 23 '24	Sale	104.80	6,312	661,479	60,899	Aug 26 08:15 PM
Korenberg Matthew E	President & COO	Aug 22 '24	Sale	105.54	1,157	122,110	67,211	Aug 26 08:15 PM
Korenberg Matthew E	Officer	Aug 22 '24	Proposed Sale	105.03	18,858	1,980,567		Aug 22 06:05 PM
Korenberg Matthew E	President & COO	Aug 09 '24	Sale	98.50	18,245	1,797,132	68,368	Aug 13 05:21 PM
Davis Todd C	Chief Executive Officer	Aug 08 '24	Buy	97.39	2,500	243,480	123,010	Aug 09 05:52 PM
Korenberg Matthew E	Officer	Aug 09 '24	Proposed Sale	98.50	18,245	1,797,132		Aug 09 05:16 PM
Gray Nancy Ryan	Director	May 09 '24	Sale	83.20	934	77,713	5,633	May 17 08:00 PM
Espinoza Octavio	Chief Financial Officer	May 17 '24	Option Exercise	55.71	6,917	385,346	28,535	May 17 07:59 PM
Espinoza Octavio	Chief Financial Officer	May 15 '24	Sale	86.01	5,873	505,148	23,882	May 17 07:59 PM
Espinoza Octavio	Chief Financial Officer	May 17 '24	Sale	86.66	5,156	446,844	23,379	May 17 07:59 PM
Espinoza Octavio	Chief Financial Officer	May 16 '24	Sale	86.00	2,264	194,712	21,618	May 17 07:59 PM
Korenberg Matthew E	President & Chief Operating	May 14 '24	Sale	85.10	14,158	1,204,912	86,263	May 15 07:34 PM
Korenberg Matthew E	President & Chief Operating	May 13 '24	Sale	84.54	3,440	290,828	100,421	May 15 07:34 PM
Reardon Andrew	Chief Legal Officer &	May 09 '24	Option Exercise	52.27	10,000	522,700	32,205	May 13 05:32 PM
Reardon Andrew	Chief Legal Officer &	May 09 '24	Sale	83.04	10,000	830,449	22,205	May 13 05:32 PM
Aryeh Jason	Director	Apr 30 '24	Option Exercise	52.30	2,406	125,834	76,828	May 02 06:07 PM
KOZARICH JOHN W	Director	Apr 24 '24	Option Exercise	39.35	2,893	113,840	42,523	Apr 26 06:35 PM
Davis Todd C	Chief Executive Officer	Mar 25 '24	Option Exercise	57.39	16,015	919,147	120,160	Mar 27 05:47 PM
Sabba Stephen L	Director	Mar 05 '24	Option Exercise	0.00	2,893	0	30,819	Mar 07 01:27 PM
Sabba Stephen L	Director	Mar 05 '24	Sale	74.30	1,893	140,650	28,926	Mar 07 01:27 PM
Aryeh Jason	Director	Mar 05 '24	Option Exercise	39.35	2,893	113,840	74,422	Mar 06 05:28 PM
Espinoza Octavio	Chief Financial Officer	Feb 28 '24	Option Exercise	56.62	1,264	71,564	29,895	Feb 29 06:50 PM
Espinoza Octavio	Chief Financial Officer	Feb 28 '24	Sale	88.46	140	12,384	29,755	Feb 29 06:50 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LGND

Ligand Pharmaceuticals, Inc

Upgrade your FINVIZ experience